Secretory Proteins, Volume 133 in the Advances in Protein Chemistry and Structural Biology series highlights new advances in the field, including chapters on Proprotein Convertases regulate trafficking and maturation of key proteins within the secretory pathway, Secretory Proteins in Cancer Diagnosis, Senescent Cells and SASP in Cancer Microenvironment: new approaches in cancer therapy, Autophagy for secretory protein: Therapeutic targets in cancer, Secretory proteins and pathways of secretion of osteosarcoma, Monocyte secretory proteins as drug targets for arresting progression of atherosclerosis, The secretory phenotypes of envenomed cells: insights into venom cytotoxicity, Macromolecules for secretory pathway in SARS-CoV-2 infection, and much more.
Other sections cover Exploring the role of secretory proteins in the human infectious diseases diagnosis and therapeutics, Secretory proteins in orchestration of microbial pathogenesis- the curious case of Staphylococcus aureus, Influence of pathological mutations in Aspartylglucosylamine Deaspartylase causing Aspartylglucosaminuria: an in silico approach, and Change in conformational dynamics of Lipase A secretory protein upon mutation causing Wolman disease.
1. Proprotein convertases regulate trafficking and maturation of key proteins within the secretory pathway Laura Cendron, Sylvia Rothenberger, Leonardo Cassari, Monica Dettin, and Antonella Pasquato 2. Exploring the macromolecules for secretory pathway in cancer disease Chandrabose Selvaraj, Umesh Panwar, Karthik Raja Ramalingam, Rajendran Vijayakumar, and Sanjeev Kumar Singh 3. Current and emerging biomarkers in ovarian cancer diagnosis: CA125 and beyond Tarang Sharma, Sabah Nisar, Tariq Masoodi, Muzafar A. Macha, Shahab Uddin, Ammira Al-Shabeeb Akil, Tej K. Pandita, Mayank Singh, and Ajaz A. Bhat 4. Senescent cells and SASP in cancer microenvironment: New approaches in cancer therapy Aysun Ozdemir, Yaprak Dilber Simay Demir, Zeynep Elif Yesilyurt, and Mustafa Ark 5. Autophagy for secretory protein: Therapeutic targets in cancer Kewal Kumar Mahapatra, Srimanta Patra, Soumya Ranjan Mishra, Bishnu Prasad Behera, Shankargouda Patil, and Sujit Kumar Bhutia 6. The role of SPARC/ON in human osteosarcoma Consolato M. Sergi 7. The secretory phenotypes of envenomed cells: Insights into venom cytotoxicity Y. Yong, J.J. Hiu, and M.K.K. Yap 8. Exploring the role of secretory proteins in the human infectious diseases diagnosis and therapeutics Elora Kalita, Mamta Panda, Abhishek Rao, and Vijay Kumar Prajapati 9. Secretory proteins in the orchestration of microbial virulence: The curious case of Staphylococcus aureus Dileep Francis, Anusha Bhairaddy, Atheene Joy, Gopika Veeramanickathadathil Hari, and Ashik Francis 10. Structure-based virtual screening to identify potential lipase inhibitors to reduce lipid storage in Wolman disorder Karthick Vasudevan, S. Udhaya Kumar, A. Mithun, B. Raghavendra, and C. George Priya Doss
Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.
